Neovacs fundraising: a 0.25 million euro operation

Neovacs, listed on Euronext Growth Paris, announced a €0.25 million fundraising through the issuance of OCEANE-BSA bonds. The net proceeds of €240,000 will be used to support the Kinoïde® allergy research program and increase investment in biotechnology and medical device projects.

This transaction comes on top of a series of fundraising rounds totaling €26.4 million, which resulted in a significant dilution of shareholders' stakes. The newly issued securities could result in the creation of up to 9,950,249 new shares. Shareholders are potentially diluted, reducing holders' stakes from 1% to 0.86%.

The company warns of the risks associated with this type of financing and recommends that investors exercise caution.